Interest grows as select pharmacies carry the HeartCheck™ PEN for sale in Ontario

TORONTO, ONTARIO – CardioComm Solutions, Inc. (“CardioComm Solutions” or the “Company”) (TSX VENTURE: EKG) today announced that Remedy’sRx pharmacies have joined the Company’s campaign to promote awareness of the HeartCheck™ PEN. Select pharmacies in more Ontario cities will now be carrying the HeartCheck™ PEN for sale to consumers.  Remedy’sRx will be recognized in the CardioComm Solutions HeartCheck™ PEN television commercial that is airing on the CBC television network until the end of October.

“The addition of Remedy’sRx to our distribution network is an indication that acceptance of the HeartCheck™ PEN and SMART Monitoring technologies continues to grow. While head office support is first required, the decision for a pharmacy to participate in the “Take Control” campaign requires independent agreement from each pharmacy location. Pharmacists are interested in introducing the new health monitoring benefits that the use of the HeartCheck™ PEN can offer to their patients. Additionally, pharmacists have expressed interest in learning more about offering in-pharmacy electrocardiogram (“ECG”) screening services for arrhythmia detection. This move would be complementary and supportive of existing pharmacy based MedsCheck services,” said Etienne Grima, CEO of CardioComm Solutions. “The Remedy’sRx pharmacy banner group is a large chain with over 110 pharmacies in Ontario alone, and we look forward to continued opportunities in taking this initiative to their pharmacy members across Canada,” added Mr. Grima.

CardioComm Solutions launched the “Take Control” campaign to target the 40+ year old market and to encourage these consumers to monitor their heart health using ECG recordings for arrhythmia detection. Last week during the Canadian Cardiovascular Congress/Vascular 2013 scientific meeting, data was presented showing that use of manual pulse check was not appropriate for detection of irregular heart rates such as is seen with atrial fibrillation. This latest evidence offers further validation for use of the HeartCheck™ devices and the SMART Monitoring ECG service heart rhythm monitoring and arrhythmia detection/identification.

“We are encouraged by the interest from pharmacists and look forward to the implementation of a pharmacy-based sales strategy for both the HeartCheck™ PEN ECG devices as well as the SMART Monitoring ECG service under our Partner Program initiative. Plans are now underway to continue the push into additional pharmacy banner groups not only in Ontario but across Canada and in the United States as well,” said Simi Grosman, member of the Board of Directors for the Company.